Inj. isatuximab-irfc 10 mg
Products billed under this code include Sarclisa.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Sarclisa.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Sarclisa | Sanofi-Aventis U.S. LLC | 00024-0654-01 | 10 | $898.12 |
| Sarclisa | Sanofi-Aventis U.S. LLC | 00024-0656-01 | 50 | $4,490.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $89.812 | +$1.652 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $88.16 | +$4.583 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted September 15, 2026 |
| 2Q26 | $83.577 | −$0.718 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted September 15, 2026 |
| 1Q26 | $84.295 | +$2.395 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted September 15, 2026 |
| 4Q25 | $81.90 | −$0.96 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted September 8, 2026 |
| 3Q25 | $82.86 | +$4.005 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted March 10, 2026 |
| 2Q25 | $78.855 | −$0.492 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted March 10, 2026 |
| 1Q25 | $79.347 | +$1.298 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted December 19, 2025 |
| 4Q24 | $78.049 | +$0.057 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 11, 2025 |
| 3Q24 | $77.992 | +$1.572 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 11, 2025 |
| 2Q24 | $76.42 | −$0.077 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted March 11, 2025 |
| 1Q24 | $76.497 | +$1.856 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted December 19, 2024 |
| 4Q23 | $74.641 | +$0.292 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted October 10, 2024 |
| 3Q23 | $74.349 | +$2.652 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 5, 2024 |
| 2Q23 | $71.697 | −$0.251 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted February 23, 2024 |
| 1Q23 | $71.948 | +$1.503 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted December 6, 2023 |
| 4Q22 | $70.445 | −$0.051 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 22, 2023 |
| 3Q22 | $70.496 | +$1.62 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 9, 2023 |
| 2Q22 | $68.876 | −$0.148 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted December 14, 2022 |
| 1Q22 | $69.024 | +$1.426 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 8, 2022 |
| 4Q21 | $67.598 | −$0.10 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 2, 2022 |
| 3Q21 | $67.698 | +$1.477 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted June 2, 2022 |
| 2Q21 | $66.221 | −$0.151 | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted March 1, 2022 |
| 1Q21 | $66.372 | – | 10 MG | Inj. isatuximab-irfc 10 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.